A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission Journal Article


Authors: Juretzka, M.; Hensley, M. L.; Tew, W.; Konner, J.; Aghajanian, C.; Leitao, M.; Iasonos, A.; Soslow, R.; Park, K.; Sabbatini, P.
Article Title: A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission
Abstract: Purpose of investigation: To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). Methods: 35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally. Results: One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS. Conclusions: Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.
Keywords: immunohistochemistry; adult; clinical article; human tissue; aged; disease-free survival; middle aged; clinical trial; fatigue; neutropenia; diarrhea; drug withdrawal; side effect; disease free survival; ovarian cancer; cytoreductive surgery; ovarian neoplasms; imatinib; drug eruption; ovary cancer; peritoneum cancer; phase 2 clinical trial; neoplasm recurrence, local; peritoneal neoplasms; anemia; nausea; neuropathy; thrombocytopenia; vomiting; creatinine blood level; platelet derived growth factor receptor; pyrimidines; abdominal pain; hyperglycemia; hypomagnesemia; protein kinase inhibitors; hypokalemia; cancer regression; remission; piperazines; platinum complex; taxane derivative; uterine tube carcinoma; fallopian tube neoplasms; administration, oral; dry eye; cellulitis; neoplasms, glandular and epithelial; petechia; peritoneal; ureter stone
Journal Title: European Journal of Gynaecological Oncology
Volume: 29
Issue: 6
ISSN: 0392-2936
Publisher: I R O G Canada, Inc  
Date Published: 2008-01-01
Start Page: 568
End Page: 572
Language: English
PUBMED: 19115680
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 17 November 2011" - "CODEN: EJGOD" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Mario Leitao
    575 Leitao
  2. Jason Konner
    155 Konner
  3. Paul J Sabbatini
    262 Sabbatini
  4. Alexia Elia Iasonos
    362 Iasonos
  5. Kay Jung Park
    305 Park
  6. Martee L Hensley
    289 Hensley
  7. Robert Soslow
    793 Soslow
  8. William P Tew
    244 Tew